© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
AAAAI
AAAAI / WAO Joint Congress as we explore the critical intersection of climate change and allergic diseases and explore their profound global implications on health. You will learn from, and connect with, renowned experts from across the globe, discover cutting-edge research and make connections that will last a lifetime. Together, we'll turn ideas into action, connect with purpose and create lasting impact.
AAAAI 2024. New data on neffy (epinephrine nasal spray) include the first report of efficacy after oral food challenge in a pediatric population at risk for anaphylaxis.
AAAAI 2024. Patients with asthma who received dupilumab plus medium-dose ICS had improved lung function and asthma control vs those who received placebo plus high-dose ICS.
AAAAI 2024. Reduction of AD signs and symptoms was significant among approximately half of study participants at 4 weeks and continuously rose through week 260, investigators report.
AAAAI 2024. Oral mucosal immunotherapy delivered via metered-dose toothpaste produced a statistically significant increase in IgG4 and a decrease in IgE/IgG4 ratio.
AAAAI 2024. The effects, seen 18 to 20 weeks after discontinuation of tezepelumab, suggest a persistent effect of thymic stromal lymphopoietin (TSLP) blockade in CSU.
AAAAI 2023. The TSLP inhibitor was superior to placebo in 2 post hoc analyses of the PATHWAY and NAVIGATOR clinical trials.
Future studies may consider PARS the new gold standard in predicting pediatric asthma risk, said study authors.
AAAAI 2023. Pandemic prescribing rates for systemic corticosteroids increased from Alpha to Delta to Omicron waves of COVID-19 but hospitalizations have dropped, study finds.
Recent research presented at AAAAI 2021 Virtual Annual Meeting suggests asthma is not an independent risk factor for severe COVID-19 or hospitalization.
Statistically significant reductions in annual exacerbation rates were seen across baseline eosinophil and exhaled FeNO level and allergy status with telepezumab, in the phase 3 NAVIGATOR trial.